Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$1,009.04 -12.37 (-1.21%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The stock has received multiple upgrades from analysts, with recent target prices reaching as high as $1,400, indicating strong confidence in the company's future performance.
  • Eli Lilly and Co has a robust pipeline of innovative therapies, which positions the company well for future growth and revenue generation.
  • The current stock price is around $1,200, reflecting a significant increase over the past year, suggesting positive market sentiment and investor interest.

Cons of Eli Lilly and Company

  • Some analysts have issued lower target prices, with one report suggesting a target as low as $850, indicating potential concerns about future performance.
  • The stock has received a "Sell" rating from one analyst, which could signal caution for potential investors.
  • Market volatility and economic uncertainties could impact the pharmaceutical sector, potentially affecting Eli Lilly and Co's stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$949.26 billion
P/E Ratio
35.81
Consensus Rating
Moderate Buy
Consensus Price Target
$1,218.33 (+20.7% Upside)
Volume
1.30 million shares
Average Volume
3.17 million shares
Today's Range
$1,003.69
$1,037.88
50-Day Range
$851.65
$1,017.68
52-Week Range
$623.78
$1,133.95
Dividend Yield
0.70%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$230.13 +0.13 (+0.06%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $230, which may present a buying opportunity for investors looking for value in a well-established company.
  • Johnson & Johnson recently reported earnings per share of $2.70, exceeding analysts' expectations, indicating strong financial performance and potential for growth.
  • The company has a solid revenue growth of nearly 10% year-over-year, showcasing its ability to expand and adapt in the healthcare market.

Cons of Johnson & Johnson

  • Insider selling has been notable, with executives recently reducing their holdings, which may signal concerns about the company's future performance.
  • The company faced a decrease in earnings per share compared to the previous year, which could indicate challenges in maintaining profitability.
  • Johnson & Johnson's stock has a relatively high P/E ratio, which may suggest that the stock is overvalued compared to its earnings potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$553.65 billion
P/E Ratio
26.59
Consensus Rating
Moderate Buy
Consensus Price Target
$253.04 (+10.0% Upside)
Volume
1.85 million shares
Average Volume
8.41 million shares
Today's Range
$229.22
$232.00
50-Day Range
$221.17
$244.48
52-Week Range
$149.04
$251.71
Dividend Yield
2.27%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$212.68 -1.08 (-0.51%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie has shown strong revenue growth, with a quarterly revenue increase of over 12% year-over-year, indicating robust business performance.
  • The current stock price is around $210, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • AbbVie recently announced a quarterly dividend of $1.73 per share, reflecting a commitment to returning value to shareholders, with an annualized dividend yield of approximately 3.3%.

Cons of AbbVie

  • AbbVie has a notably high dividend payout ratio of 340.89%, which may raise concerns about the sustainability of its dividend payments in the long term.
  • The company reported a negative return on equity of 911.57%, suggesting inefficiencies in generating profit from shareholders' equity.
  • Insider selling activity has been observed, with significant shares sold by executives, which could indicate a lack of confidence in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$375.75 billion
P/E Ratio
104.77
Consensus Rating
Moderate Buy
Consensus Price Target
$253.43 (+19.2% Upside)
Volume
1.67 million shares
Average Volume
6.98 million shares
Today's Range
$211.50
$214.50
50-Day Range
$197.24
$227.75
52-Week Range
$180.25
$244.81
Dividend Yield
3.29%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$382.25 -6.99 (-1.80%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The company recently reported a revenue of approximately $111.65 billion for the quarter, exceeding analyst expectations, which indicates strong financial performance.
  • UnitedHealth Group has announced plans to eliminate prior authorization for 30% of healthcare services, potentially streamlining processes and improving customer satisfaction, which could enhance its market position.
  • Analysts have shown confidence in the company's future profitability, with several brokerages raising their price targets significantly, suggesting a positive outlook for the stock.

Cons of UnitedHealth Group

  • Recent broader market trends indicate volatility due to inflation concerns, which could negatively impact stock performance across the board, including UnitedHealth Group.
  • There have been recent cuts to near-term earnings estimates by analysts, which may signal caution regarding the company's short-term growth prospects.
  • Despite positive developments, the company's net margin of 2.68% suggests limited profitability, which could be a concern for investors looking for high-margin businesses.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$347.13 billion
P/E Ratio
28.87
Consensus Rating
Moderate Buy
Consensus Price Target
$385.39 (+0.8% Upside)
Volume
3.10 million shares
Average Volume
9.18 million shares
Today's Range
$382.47
$393.38
50-Day Range
$259.15
$400.69
52-Week Range
$234.60
$404.15
Dividend Yield
2.26%
Novartis stock logo

5. Novartis NYSE:NVS

$151.11 +0.67 (+0.44%)
As of 01:28 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The current stock price is around $149.77, which may present a buying opportunity for investors looking for growth in the pharmaceutical sector.
  • Novartis AG has a strong consensus rating of "Hold" from analysts, indicating a stable outlook and potential for future growth.
  • The company reported a solid earnings per share (EPS) of $2.03 recently, surpassing analysts' expectations, which reflects its strong financial performance.

Cons of Novartis

  • The stock has experienced a decline of about 1.5% recently, which may indicate short-term volatility and uncertainty in the market.
  • Analysts have noted a mixed rating with two analysts assigning a "Sell" rating, suggesting potential concerns about the company's future performance.
  • Despite a strong EPS, the company reported a slight year-over-year revenue decline of 0.9%, which could raise concerns about growth sustainability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$288.27 billion
P/E Ratio
21.64
Consensus Rating
Hold
Consensus Price Target
$141.20 (-6.6% Downside)
Volume
647,122 shares
Average Volume
2.00 million shares
Today's Range
$150.23
$151.76
50-Day Range
$142.99
$163.03
52-Week Range
$111.06
$170.46
Dividend Yield
2.08%
Merck & Co., Inc. stock logo

6. Merck & Co., Inc. NYSE:MRK

$113.38 -0.86 (-0.75%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $112, which reflects a strong market position and potential for growth.
  • Merck has demonstrated solid financial performance, with a recent quarterly revenue increase of nearly 5% year-over-year, indicating robust demand for its products.
  • The company has a strong return on equity of over 27%, suggesting effective management and profitability in generating returns for shareholders.

Cons of Merck & Co., Inc.

  • The company has a relatively high price-to-earnings (P/E) ratio of around 31.66, which may indicate that the stock is overvalued compared to its earnings.
  • Merck's debt-to-equity ratio of 1.02 suggests that the company has a significant amount of debt, which could pose risks in times of economic downturns.
  • Despite recent revenue growth, the earnings per share (EPS) for the last quarter was negative, which may raise concerns about profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$279.83 billion
P/E Ratio
31.92
Consensus Rating
Moderate Buy
Consensus Price Target
$128.18 (+13.1% Upside)
Volume
3.11 million shares
Average Volume
10.84 million shares
Today's Range
$112.90
$114.95
50-Day Range
$109.33
$123.25
52-Week Range
$75.40
$125.14
Dividend Yield
3.05%
Novo Nordisk A/S stock logo

7. Novo Nordisk A/S NYSE:NVO

$44.90 +0.62 (+1.40%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $46, which may present a buying opportunity for investors looking for growth in the pharmaceutical sector.
  • Recent reports indicate a surge in demand for the Wegovy pill, with over 2 million prescriptions since January, suggesting strong market potential and revenue growth.
  • Analysts have a consensus rating of "Hold" with a target price of approximately $65.56, indicating potential upside for investors.

Cons of Novo Nordisk A/S

  • Several analysts have downgraded their ratings recently, with some moving from "buy" to "hold," indicating a cautious outlook on the stock's performance.
  • The stock has experienced volatility, with a 12-month high of $81.44 and a low of $35.12, suggesting potential risks for investors.
  • Market sentiment may be affected by competitive pressures in the pharmaceutical industry, particularly in the diabetes and obesity treatment segments.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$200.36 billion
P/E Ratio
10.53
Consensus Rating
Hold
Consensus Price Target
$65.56 (+46.0% Upside)
Volume
5.67 million shares
Average Volume
21.40 million shares
Today's Range
$44.43
$45.05
50-Day Range
$35.28
$47.13
52-Week Range
$35.12
$81.44
Dividend Yield
3.95%
Amgen stock logo

8. Amgen NASDAQ:AMGN

$331.06 +0.31 (+0.09%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $390, reflecting a strong market position and investor confidence in the company's future growth potential.
  • Amgen Inc. has received multiple upgrades from analysts, including a recent boost to a "strong-buy" rating, indicating positive sentiment and potential for price appreciation.
  • The company has a solid dividend yield of approximately 3.1%, providing investors with a steady income stream, which is particularly attractive in volatile markets.

Cons of Amgen

  • Despite recent upgrades, the consensus rating remains a "Hold," suggesting that some analysts are cautious about the stock's short-term performance.
  • Amgen Inc. has a relatively high dividend payout ratio of 70.15%, which may raise concerns about sustainability, especially if earnings do not grow as expected.
  • Recent price target adjustments by analysts indicate some uncertainty, with targets being cut from higher levels, which could signal potential challenges ahead.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$178.76 billion
P/E Ratio
23.05
Consensus Rating
Hold
Consensus Price Target
$355.19 (+7.3% Upside)
Volume
1.41 million shares
Average Volume
2.73 million shares
Today's Range
$326.80
$331.95
50-Day Range
$324.39
$377.64
52-Week Range
$267.83
$391.29
Dividend Yield
3.09%
Thermo Fisher Scientific stock logo

9. Thermo Fisher Scientific NYSE:TMO

$446.47 -1.34 (-0.30%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $615, reflecting a strong market position and investor confidence in the company's growth potential.
  • Recent upgrades from analysts, including a "strong-buy" rating from Jefferies Financial Group, indicate positive sentiment and potential for price appreciation.
  • Institutional ownership is high, with over 89% of shares held by institutional investors, suggesting strong backing and confidence from major financial entities.

Cons of Thermo Fisher Scientific

  • Recent reports indicate that some institutional investors, like Pinnacle Associates Ltd. and Applied Finance Capital Management LLC, have reduced their holdings, which may signal concerns about future performance.
  • Analysts have varied opinions on the stock, with some price targets being lowered, which could indicate potential volatility in the stock price.
  • The competitive landscape in the medical research sector is intense, and any significant advancements by competitors could impact Thermo Fisher Scientific Inc.'s market share.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$165.68 billion
P/E Ratio
24.51
Consensus Rating
Moderate Buy
Consensus Price Target
$616.10 (+38.0% Upside)
Volume
1.14 million shares
Average Volume
2.33 million shares
Today's Range
$438.66
$452.24
50-Day Range
$438.16
$531.69
52-Week Range
$385.46
$643.99
Dividend Yield
0.43%
Gilead Sciences stock logo

10. Gilead Sciences NASDAQ:GILD

$130.65 +0.15 (+0.11%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • Gilead Sciences, Inc. has received multiple recent upgrades from analysts, with target prices reaching as high as $165.00, indicating strong market confidence in the company's future performance.
  • The current stock price is around $129.58, which may present a buying opportunity for investors looking to enter at a lower price point compared to analysts' target prices.
  • With a market capitalization of approximately $160.88 billion, Gilead Sciences, Inc. is positioned as a major player in the biopharmaceutical industry, suggesting stability and growth potential.

Cons of Gilead Sciences

  • Insider selling has been observed, with significant shares sold by executives, which may raise concerns about their confidence in the company's future performance.
  • Some analysts have downgraded their ratings, indicating potential volatility and uncertainty in the stock's performance.
  • The company's debt-to-equity ratio of 0.89 suggests a moderate level of debt, which could impact financial flexibility and growth initiatives.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$162.23 billion
P/E Ratio
17.80
Consensus Rating
Moderate Buy
Consensus Price Target
$156.93 (+20.1% Upside)
Volume
2.16 million shares
Average Volume
6.69 million shares
Today's Range
$129.49
$131.95
50-Day Range
$127.75
$148.56
52-Week Range
$104.46
$157.29
Dividend Yield
2.53%
Intuitive Surgical stock logo

11. Intuitive Surgical NASDAQ:ISRG

$446.63 +5.05 (+1.14%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The company recently reported strong quarterly earnings, with earnings per share significantly exceeding analysts' expectations, indicating robust financial health and operational efficiency.
  • Intuitive Surgical, Inc. has demonstrated impressive revenue growth, with a year-over-year increase of 23%, showcasing its expanding market presence and demand for its products.
  • The current stock price is around $421, which may present a buying opportunity for investors looking to enter at a lower price point compared to its 52-week high.

Cons of Intuitive Surgical

  • The stock has a high price-to-earnings (P/E) ratio, indicating that it may be overvalued compared to its earnings, which could deter value-focused investors.
  • Recent fluctuations in stock price have shown volatility, with a beta of 1.51, suggesting that the stock is more volatile than the market, which could pose risks for conservative investors.
  • Some analysts have lowered their price targets, indicating potential concerns about future growth or market conditions that could impact the company's performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$158.09 billion
P/E Ratio
54.11
Consensus Rating
Moderate Buy
Consensus Price Target
$579.33 (+29.7% Upside)
Volume
675,705 shares
Average Volume
2.03 million shares
Today's Range
$434.50
$447.95
50-Day Range
$420.06
$493.53
52-Week Range
$417.74
$603.88
Dividend Yield
N/A
Abbott Laboratories stock logo

12. Abbott Laboratories NYSE:ABT

$88.14 -0.68 (-0.77%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $119, reflecting a moderate buy consensus among analysts, which may indicate potential for growth.
  • Abbott Laboratories has a strong dividend yield of 3.0%, providing investors with a steady income stream, which is appealing in a low-interest-rate environment.
  • Recent institutional investments, including significant acquisitions by PFA Pension and Danica Pension, suggest confidence in Abbott Laboratories' future performance.

Cons of Abbott Laboratories

  • Recent target price reductions by analysts, including a drop from $144 to $143 by Barclays, may indicate a cautious outlook on the stock's short-term performance.
  • The company's dividend payout ratio is currently at 70.59%, which, while sustainable, may limit the funds available for reinvestment into growth opportunities.
  • Insider selling activity, with 3,055 shares sold recently, could raise concerns about the confidence of company executives in the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$153.40 billion
P/E Ratio
24.67
Consensus Rating
Moderate Buy
Consensus Price Target
$119.43 (+35.5% Upside)
Volume
3.38 million shares
Average Volume
11.84 million shares
Today's Range
$87.10
$88.38
50-Day Range
$82.58
$112.69
52-Week Range
$81.97
$139.06
Dividend Yield
2.87%
Pfizer stock logo

13. Pfizer NYSE:PFE

$25.92 +0.27 (+1.03%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $28, which reflects a moderate valuation compared to its historical performance.
  • Recent analyst upgrades, including a price target increase from Morgan Stanley, indicate positive sentiment and potential for growth.
  • Pfizer Inc. has a diverse portfolio of medicines and vaccines, which can provide stability and opportunities for revenue generation across multiple therapeutic areas.

Cons of Pfizer

  • There is ongoing bearish commentary regarding Pfizer Inc.'s post-pandemic slowdown, raising concerns about its ability to sustain dividends and growth.
  • Analysts have expressed concerns about tougher vaccine demand conditions in the U.S., which could negatively impact Pfizer Inc.'s revenue from its vaccine products.
  • Some analysts have downgraded their ratings, indicating a lack of confidence in the company's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$147.64 billion
P/E Ratio
19.77
Consensus Rating
Hold
Consensus Price Target
$28.84 (+11.3% Upside)
Volume
15.37 million shares
Average Volume
42.06 million shares
Today's Range
$25.67
$26.03
50-Day Range
$25.31
$28.56
52-Week Range
$22.81
$28.75
Dividend Yield
6.79%
Stryker stock logo

14. Stryker NYSE:SYK

$320.31 +2.56 (+0.80%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The current stock price is around $292, which may present a buying opportunity for investors looking for value in the medical technology sector.
  • Stryker Co. has a strong market presence with a market capitalization of approximately $111.88 billion, indicating stability and growth potential.
  • The company reported a quarterly revenue increase of 2.6% compared to the same quarter last year, showcasing its ability to grow even in challenging market conditions.

Cons of Stryker

  • The company recently missed earnings expectations, reporting $2.60 earnings per share (EPS) against a consensus estimate of $2.98, which may raise concerns about its profitability.
  • There has been insider selling, with a vice president selling over 5,000 shares, which could indicate a lack of confidence in the company's short-term prospects.
  • UBS Group has downgraded its price target for Stryker Co. from $400 to $380, reflecting a more cautious outlook from analysts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$122.71 billion
P/E Ratio
37.05
Consensus Rating
Moderate Buy
Consensus Price Target
$395.48 (+23.5% Upside)
Volume
1.25 million shares
Average Volume
2.21 million shares
Today's Range
$313.98
$319.78
50-Day Range
$282.85
$366.05
52-Week Range
$281.00
$404.87
Dividend Yield
1.15%
Danaher stock logo

15. Danaher NYSE:DHR

$169.39 +2.35 (+1.41%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The current stock price is around $174, reflecting a stable market position and potential for growth.
  • Danaher Co. has a strong market capitalization of approximately $123.64 billion, indicating a robust financial foundation.
  • The company recently declared a quarterly dividend of $0.40 per share, which translates to an annualized yield of 1.0%, providing a return on investment for shareholders.

Cons of Danaher

  • The stock has experienced fluctuations, with a fifty-two week high of $242.80 and a low of $172.34, indicating potential volatility.
  • Danaher Co. has a relatively high price-to-earnings ratio compared to industry averages, which may suggest that the stock is overvalued.
  • Insider ownership is at 10.80%, which may raise concerns about the alignment of interests between management and shareholders.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$119.75 billion
P/E Ratio
32.73
Consensus Rating
Moderate Buy
Consensus Price Target
$238.65 (+40.9% Upside)
Volume
1.42 million shares
Average Volume
4.36 million shares
Today's Range
$164.10
$169.36
50-Day Range
$161.95
$198.85
52-Week Range
$160.93
$242.80
Dividend Yield
0.99%
CVS Health stock logo

16. CVS Health NYSE:CVS

$93.66 -0.52 (-0.55%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. recently reported a strong Q1 performance with adjusted earnings per share significantly exceeding estimates, indicating robust operational efficiency and profitability.
  • The current stock price is around $87.70, which reflects a potential upside based on recent analyst target price increases, suggesting that the stock may be undervalued.
  • Analysts have raised their price targets for CVS Health Co., with several maintaining a "buy" rating, indicating positive sentiment and confidence in the company's future growth.

Cons of CVS Health

  • Despite recent positive developments, some analysts remain cautious, with a notable firm maintaining a "hold" rating and a price target below the current stock price, indicating limited near-term upside potential.
  • The company's debt-to-equity ratio suggests a moderate level of debt, which could pose risks if not managed effectively, especially in a fluctuating economic environment.
  • While recent earnings were strong, the overall market sentiment can shift quickly, and any negative news could impact stock performance significantly.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$119.45 billion
P/E Ratio
41.24
Consensus Rating
Moderate Buy
Consensus Price Target
$98.68 (+5.4% Upside)
Volume
2.58 million shares
Average Volume
8.66 million shares
Today's Range
$93.39
$96.37
50-Day Range
$69.98
$98.14
52-Week Range
$58.50
$98.43
Dividend Yield
2.77%
Bristol Myers Squibb stock logo

17. Bristol Myers Squibb NYSE:BMY

$58.50 +0.20 (+0.33%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The current stock price is around $56.10, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Analysts have recently increased their earnings per share estimates for FY2026, indicating positive growth expectations for the company.
  • Bristol-Myers Squibb has a diverse portfolio of products, including recent advancements in treatments for various cancers and autoimmune diseases, which can drive future revenue growth.

Cons of Bristol Myers Squibb

  • The company has a relatively high debt-to-equity ratio of 2.10, which may indicate financial risk and could affect its ability to invest in new projects or weather economic downturns.
  • Recent target price adjustments by analysts, such as a decrease from $68.00 to $67.00, may signal concerns about the company's short-term performance.
  • Despite a strong product lineup, competition in the biopharmaceutical industry is intense, which could impact market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$119.44 billion
P/E Ratio
16.43
Consensus Rating
Hold
Consensus Price Target
$61.31 (+4.8% Upside)
Volume
2.60 million shares
Average Volume
12.15 million shares
Today's Range
$58.11
$59.21
50-Day Range
$55.62
$61.79
52-Week Range
$42.52
$62.89
Dividend Yield
4.40%
Vertex Pharmaceuticals stock logo

18. Vertex Pharmaceuticals NASDAQ:VRTX

$429.30 -5.01 (-1.15%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The current stock price is around $427.65, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
  • Vertex Pharmaceuticals Incorporated has received multiple "buy" ratings from analysts, indicating strong confidence in the company's future performance.
  • The company reported a significant increase in quarterly revenue, showcasing its ability to grow and adapt in a competitive market.

Cons of Vertex Pharmaceuticals

  • Despite strong performance, the stock has a relatively high P/E ratio, which may indicate that it is overvalued compared to its earnings.
  • Vertex Pharmaceuticals Incorporated operates in a highly competitive biotechnology market, which could impact its market share and profitability.
  • Recent price target adjustments by analysts suggest some uncertainty about the stock's future performance, which could lead to volatility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$108.96 billion
P/E Ratio
25.46
Consensus Rating
Moderate Buy
Consensus Price Target
$555.17 (+29.3% Upside)
Volume
827,194 shares
Average Volume
1.37 million shares
Today's Range
$427.64
$439.98
50-Day Range
$423.24
$499.17
52-Week Range
$362.50
$507.92
Dividend Yield
N/A
Sanofi stock logo

19. Sanofi NASDAQ:SNY

$44.68 +1.13 (+2.58%)
As of 01:28 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi has recently raised its dividend by over 10%, indicating strong financial health and a commitment to returning value to shareholders.
  • The current stock price is around $43, which may present a buying opportunity for investors looking for value in the biopharma sector.
  • Analysts have given Sanofi a consensus target price of $51, suggesting potential upside from the current trading levels.

Cons of Sanofi

  • Recent downgrades from analysts, including a shift from "buy" to "neutral" ratings, may indicate concerns about the company's growth prospects.
  • Sanofi's stock has experienced fluctuations, with a 52-week low of $42.78, which could signal volatility and risk for investors.
  • The company's debt-to-equity ratio is relatively low, which might suggest limited leverage for growth opportunities compared to competitors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$108.95 billion
P/E Ratio
12.48
Consensus Rating
Hold
Consensus Price Target
$51.00 (+14.2% Upside)
Volume
1.74 million shares
Average Volume
3.67 million shares
Today's Range
$44.30
$44.81
50-Day Range
$42.42
$48.18
52-Week Range
$42.33
$53.36
Dividend Yield
4.06%
GSK stock logo

20. GSK NYSE:GSK

$51.08 +0.03 (+0.05%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $51.65, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • GSK plc has a solid dividend payout ratio of 38.8%, indicating that the company is generating sufficient earnings to cover its dividend payments, which can provide a steady income stream for investors.
  • Recent quarterly earnings showed a significant revenue increase of 6.2% year-over-year, suggesting strong operational performance and growth potential.

Cons of GSK

  • GSK plc has decreased its dividend payment by an average of 0.1% annually over the last three years, which may raise concerns about the company's long-term commitment to returning value to shareholders.
  • The company has a relatively high debt-to-equity ratio of 0.92, indicating that it relies on debt financing, which can be risky in volatile market conditions.
  • Despite recent revenue growth, the company's earnings per share (EPS) forecast for the current year is lower than previous expectations, which could signal potential challenges ahead.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$103.66 billion
P/E Ratio
13.28
Consensus Rating
Reduce
Consensus Price Target
$53.00 (+3.8% Upside)
Volume
1.25 million shares
Average Volume
5.00 million shares
Today's Range
$50.68
$51.27
50-Day Range
$49.66
$59.19
52-Week Range
$35.45
$61.69
Dividend Yield
3.65%
Medtronic stock logo

21. Medtronic NYSE:MDT

$77.65 -0.93 (-1.19%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The stock currently has a consensus target price of approximately $107.80, indicating potential for price appreciation based on analyst expectations.
  • Medtronic plc has received multiple "buy" ratings from analysts, suggesting strong confidence in the company's growth and performance in the medical technology sector.
  • As a leading global medical technology company, Medtronic plc is well-positioned to benefit from the increasing demand for innovative healthcare solutions and therapeutic devices.

Cons of Medtronic

  • Recent downgrades from analysts, including a shift from "buy" to "hold," may indicate concerns about the company's short-term performance and market conditions.
  • One of the company's executives recently sold a significant number of shares, which could raise concerns about insider confidence in the stock's future performance.
  • Despite a strong product lineup, the competitive landscape in the medical technology sector is intense, which could impact Medtronic plc's market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$99.67 billion
P/E Ratio
21.62
Consensus Rating
Moderate Buy
Consensus Price Target
$107.80 (+38.8% Upside)
Volume
3.98 million shares
Average Volume
8.72 million shares
Today's Range
$77.35
$78.60
50-Day Range
$74.56
$91.26
52-Week Range
$74.40
$106.33
Dividend Yield
3.67%
McKesson stock logo

22. McKesson NYSE:MCK

$753.40 -8.49 (-1.11%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $735, which reflects a strong market position and potential for growth.
  • Recent analyst upgrades, including Barclays raising their price target to $1,050, indicate positive market sentiment and confidence in the company's future performance.
  • McKesson Co. has a solid market capitalization of approximately $88 billion, suggesting stability and a strong presence in the healthcare sector.

Cons of McKesson

  • Insider sales have been significant, with over 3,264 shares sold recently, which may raise concerns about the executives' confidence in the company's short-term performance.
  • The stock has experienced fluctuations, with a one-year high of $999 and a low of $637, indicating volatility that could deter risk-averse investors.
  • Despite a strong market presence, the company's insider ownership is only 0.08%, which may suggest a lack of alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$90.64 billion
P/E Ratio
19.60
Consensus Rating
Moderate Buy
Consensus Price Target
$968.87 (+28.6% Upside)
Volume
390,256 shares
Average Volume
843,545 shares
Today's Range
$751.48
$765.51
50-Day Range
$724.87
$943.88
52-Week Range
$637.00
$999.00
Dividend Yield
0.42%
HCA Healthcare stock logo

23. HCA Healthcare NYSE:HCA

$399.50 -5.19 (-1.28%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The current stock price is around $540, reflecting a strong market interest in HCA Healthcare, Inc. despite recent adjustments from analysts.
  • HCA Healthcare, Inc. reported a revenue increase of 4.3% compared to the same quarter last year, indicating growth in its operations and demand for its services.
  • The company has a consensus rating of "Moderate Buy" from analysts, suggesting positive sentiment and potential for future price appreciation.

Cons of HCA Healthcare

  • The company recently missed earnings per share estimates, which may raise concerns about its short-term financial performance and operational efficiency.
  • HCA Healthcare, Inc. has a negative return on equity, which indicates that the company is not generating profit effectively from its equity base, potentially deterring investors.
  • Recent downgrades from several analysts, including a shift from "buy" to "hold," suggest a cautious outlook on the stock's near-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$88.48 billion
P/E Ratio
13.72
Consensus Rating
Moderate Buy
Consensus Price Target
$515.77 (+29.1% Upside)
Volume
1.02 million shares
Average Volume
1.15 million shares
Today's Range
$394.74
$404.74
50-Day Range
$403.98
$545.88
52-Week Range
$330.00
$556.52
Dividend Yield
0.74%
Elevance Health stock logo

24. Elevance Health NYSE:ELV

$393.45 -8.82 (-2.19%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$85.55 billion
P/E Ratio
16.76
Consensus Rating
Moderate Buy
Consensus Price Target
$396.16 (+0.7% Upside)
Volume
472,043 shares
Average Volume
1.84 million shares
Today's Range
$392.37
$408.00
50-Day Range
$280.80
$402.32
52-Week Range
$273.71
$411.31
Dividend Yield
1.75%
Boston Scientific stock logo

25. Boston Scientific NYSE:BSX

$56.38 -0.43 (-0.76%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The current stock price is around $64, which is significantly lower than its 52-week high of $109.50, presenting a potential buying opportunity for investors looking for value.
  • Boston Scientific Co. reported a strong quarterly revenue of $5.20 billion, exceeding analyst expectations, indicating robust business performance and growth potential.
  • The company has a solid return on equity of 19.17%, suggesting effective management and profitability, which can be attractive to investors seeking reliable returns.

Cons of Boston Scientific

  • Recent stockholder proposals, including one to allow shareholders to call special meetings with only 10% of shares, were not passed, which may indicate governance issues that could concern investors.
  • The company is currently facing litigation related to securities fraud allegations, which could pose financial risks and affect investor confidence.
  • Despite a strong quarterly performance, the stock has seen significant fluctuations, with a 52-week low of $52.81, suggesting volatility that may deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$83.69 billion
P/E Ratio
23.56
Consensus Rating
Moderate Buy
Consensus Price Target
$92.71 (+64.4% Upside)
Volume
8.09 million shares
Average Volume
16.58 million shares
Today's Range
$55.33
$56.91
50-Day Range
$52.67
$71.88
52-Week Range
$52.52
$109.50
Dividend Yield
N/A
Cigna Group stock logo

26. Cigna Group NYSE:CI

$284.61 -6.67 (-2.29%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The Cigna Group has shown a solid quarterly revenue increase of approximately 4.6% compared to the same quarter last year, indicating strong business performance and growth potential.
  • The current stock price is around $288.91, which reflects a stable valuation in the market, making it an attractive option for investors looking for growth in the health services sector.
  • The company has a favorable dividend yield of 2.1%, providing investors with a steady income stream, which is particularly appealing in a low-interest-rate environment.

Cons of Cigna Group

  • Insider selling has been notable, with a total of 205,904 shares sold recently, which may signal a lack of confidence among insiders regarding the company's future performance.
  • Despite the positive revenue growth, the stock has experienced fluctuations, and the recent insider transactions could indicate potential volatility ahead.
  • The company operates in a highly competitive health services market, which could impact its ability to maintain growth and profitability in the long term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$75.34 billion
P/E Ratio
12.07
Consensus Rating
Moderate Buy
Consensus Price Target
$338.55 (+19.0% Upside)
Volume
405,063 shares
Average Volume
1.69 million shares
Today's Range
$284.03
$292.36
50-Day Range
$257.97
$300.36
52-Week Range
$239.51
$338.89
Dividend Yield
2.19%
Regeneron Pharmaceuticals stock logo

27. Regeneron Pharmaceuticals NASDAQ:REGN

$644.25 +13.95 (+2.21%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $701, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
  • Regeneron Pharmaceuticals, Inc. has recently reported strong quarterly earnings, with earnings per share exceeding expectations, indicating robust financial health and operational efficiency.
  • The company has a diverse pipeline of biologic therapies, which positions it well for future growth in various therapeutic areas, potentially leading to increased revenue streams.

Cons of Regeneron Pharmaceuticals

  • Despite recent successes, the stock has experienced volatility, which may deter risk-averse investors looking for stable returns.
  • Some analysts have downgraded their ratings, indicating mixed opinions on the stock's future performance, which could lead to uncertainty in the market.
  • The company faces competition in the biotechnology space, which could impact its market share and profitability in the long term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$68.13 billion
P/E Ratio
15.70
Consensus Rating
Moderate Buy
Consensus Price Target
$792.65 (+23.0% Upside)
Volume
486,115 shares
Average Volume
780,702 shares
Today's Range
$633.60
$651.00
50-Day Range
$629.68
$781.60
52-Week Range
$476.49
$821.11
Dividend Yield
0.60%
Takeda Pharmaceutical stock logo

28. Takeda Pharmaceutical NYSE:TAK

$16.70 +0.12 (+0.69%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is around $16.65, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Takeda Pharmaceutical Company Limited has received a recent upgrade to a "strong-buy" rating, indicating positive sentiment from analysts regarding its future performance.
  • The company is launching a new transformation program aimed at achieving significant cost savings, which could enhance profitability and shareholder value in the coming years.

Cons of Takeda Pharmaceutical

  • The company reported a quarterly earnings miss, with earnings per share falling short of analyst expectations, which may raise concerns about its financial performance.
  • Takeda has a relatively high P/E ratio of 69.36, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Restructuring costs associated with the transformation program could impact short-term profitability, leading to potential volatility in the stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$53.13 billion
P/E Ratio
42.81
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
938,140 shares
Average Volume
3.01 million shares
Today's Range
$16.56
$16.71
50-Day Range
$16.31
$18.77
52-Week Range
$12.99
$18.90
Dividend Yield
3.04%
Cencora stock logo

29. Cencora NYSE:COR

$264.93 -1.24 (-0.46%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is around $254.90, which may present a buying opportunity given analysts' target prices suggesting significant upside potential.
  • Cencora, Inc. has received multiple "buy" ratings from analysts, indicating strong confidence in the company's future performance.
  • The company reported a year-over-year revenue increase of 5.5%, showcasing its ability to grow even in challenging market conditions.

Cons of Cencora

  • The company has a high debt-to-equity ratio of 3.62, indicating that it relies heavily on debt financing, which can be risky if market conditions change.
  • Despite positive revenue growth, the net margin is only 0.50%, suggesting that profitability may be a concern for investors looking for strong returns.
  • Analysts have varying target prices, with some estimates as low as $355.00, which could indicate uncertainty about the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$51.55 billion
P/E Ratio
20.32
Consensus Rating
Moderate Buy
Consensus Price Target
$380.25 (+43.5% Upside)
Volume
957,849 shares
Average Volume
1.53 million shares
Today's Range
$262.50
$267.53
50-Day Range
$253.20
$361.80
52-Week Range
$244.82
$377.54
Dividend Yield
0.92%
argenex stock logo

30. argenex NASDAQ:ARGX

$800.78 +3.02 (+0.38%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The current stock price is around $805, reflecting strong market interest and potential for growth.
  • argenx SE has a robust pipeline of therapies targeting severe autoimmune diseases, including its lead product candidate, efgartigimod, which has shown promise in treating conditions like myasthenia gravis.
  • The company has a significant market capitalization of over $50 billion, indicating a strong position in the biotechnology sector.

Cons of argenex

  • The stock has experienced volatility, with a 1-year high of $934.62 and a low of $510.05, indicating potential risks associated with price fluctuations.
  • Despite positive growth prospects, the company has a relatively high price-to-earnings ratio, which may suggest that the stock is overvalued compared to its earnings.
  • There is competition in the biotechnology sector, and the success of argenx SE's therapies is not guaranteed, which could impact future revenue.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$49.56 billion
P/E Ratio
35.66
Consensus Rating
Moderate Buy
Consensus Price Target
$1,017.78 (+27.1% Upside)
Volume
95,685 shares
Average Volume
356,476 shares
Today's Range
$797.31
$807.12
50-Day Range
$663.93
$849.04
52-Week Range
$510.05
$934.62
Dividend Yield
N/A
Edwards Lifesciences stock logo

31. Edwards Lifesciences NYSE:EW

$82.21 +0.05 (+0.06%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The current stock price is around $82, reflecting a stable position in the market.
  • Edwards Lifesciences Co. reported a significant revenue increase of 16.7% compared to the same quarter last year, indicating strong growth potential.
  • The company has a solid net margin of 17.39%, showcasing effective cost management and profitability.

Cons of Edwards Lifesciences

  • The price-to-earnings (PE) ratio of 44.72 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Insider selling activity has been notable, with significant shares sold recently, which may raise concerns about the company's future prospects.
  • The beta of 0.87 indicates that the stock is less volatile than the market, which might not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.36 billion
P/E Ratio
43.75
Consensus Rating
Moderate Buy
Consensus Price Target
$95.65 (+16.4% Upside)
Volume
2.04 million shares
Average Volume
4.76 million shares
Today's Range
$81.23
$83.59
50-Day Range
$77.11
$85.76
52-Week Range
$72.30
$87.89
Dividend Yield
N/A
Cardinal Health stock logo

32. Cardinal Health NYSE:CAH

$200.19 -0.18 (-0.09%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • Analysts maintain a generally positive outlook, with several firms recently raising their price targets, indicating confidence in the company's future performance.
  • The current stock price is around $245, reflecting a stable position in the market despite recent fluctuations.
  • Cardinal Health, Inc. has reported strong earnings per share (EPS) performance, which can signal profitability and operational efficiency to investors.

Cons of Cardinal Health

  • Recent revenue figures missed expectations, which can lead to short-term selling pressure and indicate potential challenges in meeting market demands.
  • GAAP results showed a decline in operating earnings and EPS, primarily due to a significant goodwill impairment charge, which can raise concerns about the company's financial health.
  • The mixed nature of recent financial reports, with strong EPS but weak revenue, may create uncertainty and volatility, potentially deterring some investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$46.86 billion
P/E Ratio
30.60
Consensus Rating
Moderate Buy
Consensus Price Target
$241.80 (+20.8% Upside)
Volume
722,631 shares
Average Volume
1.89 million shares
Today's Range
$198.58
$201.06
50-Day Range
$182.62
$222.30
52-Week Range
$137.75
$233.60
Dividend Yield
1.02%
IDEXX Laboratories stock logo

33. IDEXX Laboratories NASDAQ:IDXX

$549.73 +3.24 (+0.59%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $528, which reflects a strong market position and potential for growth.
  • IDEXX Laboratories, Inc. reported a significant increase in quarterly revenue, up 14.3% year-over-year, indicating robust demand for its diagnostic products and services.
  • The company has a high return on equity of 70.87%, suggesting effective management and profitability, which can lead to higher shareholder returns.

Cons of IDEXX Laboratories

  • The stock has experienced volatility, with a one-year high of $769.98 and a low of $496.61, indicating potential risks associated with price fluctuations.
  • The price-to-earnings (P/E) ratio is relatively high at 38.94, which may suggest that the stock is overvalued compared to its earnings, potentially limiting upside for new investors.
  • The company has a beta of 1.58, indicating that its stock price is more volatile than the market, which could lead to higher risk for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.32 billion
P/E Ratio
40.44
Consensus Rating
Moderate Buy
Consensus Price Target
$751.00 (+36.6% Upside)
Volume
233,122 shares
Average Volume
539,573 shares
Today's Range
$535.95
$551.71
50-Day Range
$528.68
$610.45
52-Week Range
$496.61
$769.98
Dividend Yield
N/A
Haleon stock logo

34. Haleon NYSE:HLN

$9.28 +0.09 (+0.92%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The current stock price is around $9.59, which may present a buying opportunity for investors looking for value in the consumer healthcare sector.
  • Haleon plc has a strong consensus rating of "Moderate Buy" from analysts, indicating positive sentiment and potential for price appreciation.
  • The company recently announced a dividend of $0.1307, reflecting a commitment to returning value to shareholders, with a notable dividend yield.

Cons of Haleon

  • Deutsche Bank downgraded Haleon from a "hold" to a "sell" rating, indicating potential concerns about the company's short-term performance.
  • The stock has experienced fluctuations, with a 12-month low of $8.71, which may raise concerns about its volatility and market perception.
  • Haleon's current ratio of 0.92 suggests that the company may face challenges in meeting its short-term liabilities, which could impact financial stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$41.22 billion
P/E Ratio
23.81
Consensus Rating
Moderate Buy
Consensus Price Target
$13.40 (+44.3% Upside)
Volume
5.25 million shares
Average Volume
8.52 million shares
Today's Range
$9.15
$9.29
50-Day Range
$8.91
$10.60
52-Week Range
$8.71
$11.42
Dividend Yield
2.75%
Becton, Dickinson and Company stock logo

35. Becton, Dickinson and Company NYSE:BDX

$148.35 +1.40 (+0.95%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The current stock price is around $154, which may present a buying opportunity given analysts' recent price target increases.
  • Becton, Dickinson and Company has raised its full-year adjusted EPS guidance, indicating strong financial performance and growth potential.
  • The company returned approximately $2.3 billion to shareholders recently, including significant share repurchases, which can enhance shareholder value.

Cons of Becton, Dickinson and Company

  • The company is currently facing an FDA warning letter related to its El Paso facility, which could impact its reputation and operational capabilities.
  • Despite recent price target increases, some analysts have downgraded their ratings, indicating mixed sentiment in the market.
  • There are concerns regarding the company's debt levels, as it ended the quarter with net leverage above its long-term target, which could limit financial flexibility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.89 billion
P/E Ratio
37.57
Consensus Rating
Hold
Consensus Price Target
$184.86 (+24.6% Upside)
Volume
1.03 million shares
Average Volume
2.90 million shares
Today's Range
$144.63
$148.63
50-Day Range
$142.36
$165.34
52-Week Range
$127.59
$187.35
Dividend Yield
2.95%
Teva Pharmaceutical Industries stock logo

36. Teva Pharmaceutical Industries NYSE:TEVA

$34.33 +0.26 (+0.77%)
As of 01:28 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Market Capitalization
$39.42 billion
P/E Ratio
25.78
Consensus Rating
Moderate Buy
Consensus Price Target
$41.78 (+21.7% Upside)
Volume
1.88 million shares
Average Volume
7.98 million shares
Today's Range
$34.08
$34.55
50-Day Range
$28.37
$36.36
52-Week Range
$14.99
$37.35
Dividend Yield
N/A
Alnylam Pharmaceuticals stock logo

37. Alnylam Pharmaceuticals NASDAQ:ALNY

$294.04 -0.26 (-0.09%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The stock has shown resilience with a current price around $308, indicating potential for recovery and growth in the biotech sector.
  • Analysts have a consensus rating of "Moderate Buy" with a target price averaging around $472.78, suggesting significant upside potential.
  • Recent insider transactions indicate confidence in the company, with executives selling shares primarily for tax obligations rather than lack of faith in the company's future.

Cons of Alnylam Pharmaceuticals

  • The stock has experienced volatility, with a 12-month high of $495.55 and a low of $240.00, indicating potential risks associated with price fluctuations.
  • Recent analyst reports have shown some downgrades in price targets, which may reflect concerns about the company's short-term performance.
  • Insider ownership is relatively low at around 0.86%, which could suggest a lack of alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.23 billion
P/E Ratio
80.29
Consensus Rating
Moderate Buy
Consensus Price Target
$463.13 (+57.5% Upside)
Volume
270,311 shares
Average Volume
1.27 million shares
Today's Range
$292.10
$300.08
50-Day Range
$284.84
$339.41
52-Week Range
$284.19
$495.55
Dividend Yield
N/A
Humana stock logo

38. Humana NYSE:HUM

$307.65 -2.90 (-0.94%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • Humana Inc. recently reported earnings per share (EPS) of $10.31, exceeding analysts' expectations, which indicates strong financial performance and potential for future growth.
  • The company has shown significant revenue growth, with a 23.5% increase compared to the same quarter last year, suggesting robust demand for its services.
  • Humana Inc. has a current stock price around $235, which reflects a potential upside based on recent analyst price targets, indicating that the stock may be undervalued.

Cons of Humana

  • Despite recent growth, Humana Inc. has faced downgrades from some analysts, which may indicate concerns about future performance and market conditions.
  • The company has a relatively low net margin of 0.82%, which could suggest challenges in maintaining profitability compared to competitors.
  • Humana Inc. has a beta of 0.44, indicating lower volatility compared to the market, which may limit potential high returns for aggressive investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.96 billion
P/E Ratio
32.93
Consensus Rating
Hold
Consensus Price Target
$260.83 (-15.2% Downside)
Volume
567,184 shares
Average Volume
2.00 million shares
Today's Range
$304.56
$315.66
50-Day Range
$163.80
$309.85
52-Week Range
$163.11
$315.66
Dividend Yield
1.16%
BeOne Medicines stock logo

39. BeOne Medicines NASDAQ:ONC

$305.50 +8.49 (+2.86%)
As of 01:28 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$33.57 billion
P/E Ratio
68.45
Consensus Rating
Moderate Buy
Consensus Price Target
$389.15 (+27.4% Upside)
Volume
147,581 shares
Average Volume
253,052 shares
Today's Range
$300.15
$307.46
50-Day Range
$274.73
$323.87
52-Week Range
$234.80
$385.22
Dividend Yield
N/A
Zoetis stock logo

40. Zoetis NYSE:ZTS

$79.80 +0.88 (+1.12%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $86.99, which may present a buying opportunity for investors looking for value in the market.
  • Zoetis Inc. has a strong market capitalization of approximately $36.59 billion, indicating a solid position in the industry.
  • Recent analyst ratings show a consensus target price of $151.75, suggesting potential upside for investors based on current valuations.

Cons of Zoetis

  • Recent trading has been affected by negative headlines and a guidance cut, leading to a sharp drop in share price.
  • Several analysts have downgraded their ratings, with some reducing target prices significantly, indicating a cautious outlook.
  • The company has a relatively high debt-to-equity ratio of 2.71, which may raise concerns about financial stability and leverage.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.46 billion
P/E Ratio
13.23
Consensus Rating
Hold
Consensus Price Target
$134.75 (+68.9% Upside)
Volume
3.25 million shares
Average Volume
5.10 million shares
Today's Range
$77.25
$79.75
50-Day Range
$74.11
$122.69
52-Week Range
$72.38
$172.23
Dividend Yield
2.73%
Waters stock logo

41. Waters NYSE:WAT

$340.58 +7.33 (+2.20%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Market Capitalization
$33.39 billion
P/E Ratio
43.21
Consensus Rating
Moderate Buy
Consensus Price Target
$396.00 (+16.3% Upside)
Volume
410,074 shares
Average Volume
1.08 million shares
Today's Range
$323.85
$341.73
50-Day Range
$283.58
$355.12
52-Week Range
$275.05
$414.15
Dividend Yield
N/A
Alcon stock logo

42. Alcon NYSE:ALC

$67.39 +1.11 (+1.67%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • Recent analyst ratings show strong support for Alcon Inc., with multiple firms issuing buy ratings, indicating positive market sentiment.
  • The median price target from analysts is around $94.5, suggesting potential upside from the current stock price.
  • Alcon Inc. has seen significant institutional interest, with numerous investors adding shares to their portfolios, reflecting confidence in the company's future performance.

Cons of Alcon

  • Recent hedge fund activity shows some large investors have significantly reduced their positions, which could indicate a lack of confidence in the stock's short-term performance.
  • There has been a recent sale of Alcon Inc. stock by a member of Congress, which may raise concerns about insider sentiment.
  • Despite positive analyst ratings, the stock has faced volatility, which could pose risks for investors seeking stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.32 billion
P/E Ratio
40.58
Consensus Rating
Moderate Buy
Consensus Price Target
$85.12 (+26.3% Upside)
Volume
1.25 million shares
Average Volume
1.78 million shares
Today's Range
$65.93
$67.85
50-Day Range
$61.98
$81.89
52-Week Range
$61.83
$92.55
Dividend Yield
N/A
Revolution Medicines stock logo

43. Revolution Medicines NASDAQ:RVMD

$149.93 +2.63 (+1.78%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization
$31.86 billion
P/E Ratio
N/A
Consensus Rating
Buy
Consensus Price Target
$108.88 (-27.4% Downside)
Volume
1.35 million shares
Average Volume
3.37 million shares
Today's Range
$148.28
$153.55
50-Day Range
$92.51
$152.54
52-Week Range
$34.00
$155.70
Dividend Yield
N/A
Agilent Technologies stock logo

44. Agilent Technologies NYSE:A

$111.57 +1.00 (+0.90%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The current stock price is around $114.84, which may present a buying opportunity for investors looking for growth in the medical research sector.
  • Agilent Technologies, Inc. reported a revenue increase of 7.0% compared to the same quarter last year, indicating strong business performance and potential for future growth.
  • The company has a solid return on equity of 24.49%, suggesting effective management and profitability, which can be attractive to investors seeking reliable returns.

Cons of Agilent Technologies

  • The company recently missed earnings expectations, reporting $1.36 EPS compared to the consensus estimate of $1.37, which may raise concerns about its short-term performance.
  • Agilent Technologies, Inc. has seen its stock price decline from a 12-month high of $160.27, which could indicate a downward trend that investors should be cautious of.
  • The company has a relatively high P/E ratio of 25.35, which may suggest that the stock is overvalued compared to its earnings, potentially deterring value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.49 billion
P/E Ratio
24.60
Consensus Rating
Buy
Consensus Price Target
$163.71 (+46.7% Upside)
Volume
1.04 million shares
Average Volume
2.16 million shares
Today's Range
$108.35
$111.63
50-Day Range
$110.35
$122.10
52-Week Range
$107.07
$160.27
Dividend Yield
0.91%
ResMed stock logo

45. ResMed NYSE:RMD

$210.39 +2.61 (+1.26%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The current stock price is around $217, which is significantly lower than its 52-week high, indicating potential for recovery and growth.
  • ResMed Inc. has shown strong quarterly earnings performance, recently reporting earnings per share (EPS) that exceeded analysts' expectations, reflecting solid financial health.
  • The company has a low debt-to-equity ratio, suggesting a strong balance sheet and lower financial risk, which is attractive for long-term investors.

Cons of ResMed

  • Recent stock performance has seen a decline, with the stock reaching a new 1-year low, which may indicate underlying issues or market concerns.
  • Some analysts have downgraded their ratings on ResMed Inc., suggesting a cautious outlook that could impact investor confidence.
  • Institutional investors have recently reduced their positions in ResMed Inc., which may signal a lack of confidence in the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.70 billion
P/E Ratio
20.32
Consensus Rating
Moderate Buy
Consensus Price Target
$286.18 (+36.0% Upside)
Volume
573,847 shares
Average Volume
1.15 million shares
Today's Range
$207.28
$211.74
50-Day Range
$198.87
$253.03
52-Week Range
$198.61
$293.81
Dividend Yield
1.18%
Royalty Pharma stock logo

46. Royalty Pharma NASDAQ:RPRX

$53.16 +0.75 (+1.43%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More about Royalty Pharma

Pros of Royalty Pharma

  • The current stock price is around $49.47, which reflects a strong performance in the market and may indicate potential for growth.
  • Royalty Pharma plc has a solid annualized dividend of $0.94, providing a yield of 1.9%, which can be attractive for income-focused investors.
  • Analysts have recently upgraded their ratings on the stock, with multiple firms giving it a "buy" rating, suggesting positive sentiment and confidence in future performance.

Cons of Royalty Pharma

  • The company has a relatively high P/E ratio of 36.64, which may suggest that the stock is overvalued compared to its earnings, potentially limiting future price appreciation.
  • Insider selling has been significant, with over 382,000 shares sold recently, which could indicate a lack of confidence from those closest to the company.
  • The stock has a beta of 0.40, suggesting lower volatility compared to the market, which may limit potential gains during bullish market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.60 billion
P/E Ratio
36.14
Consensus Rating
Buy
Consensus Price Target
$53.71 (+1.0% Upside)
Volume
1.02 million shares
Average Volume
3.54 million shares
Today's Range
$52.62
$53.27
50-Day Range
$45.36
$53.40
52-Week Range
$32.15
$53.47
Dividend Yield
1.81%
GE HealthCare Technologies stock logo

47. GE HealthCare Technologies NASDAQ:GEHC

$63.72 +2.14 (+3.47%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The company has recently combined its Imaging and Advanced Visualization Solutions into Advanced Imaging Solutions, which is expected to enhance operational efficiency and drive growth over time.
  • Insider buying activity has been noted, with key executives purchasing shares at around $60.45 and $59.92, indicating confidence in the company's future performance.
  • GE HealthCare Technologies Inc. has a diverse portfolio that includes advanced diagnostic imaging systems, which are critical in modern healthcare, potentially leading to sustained demand.

Cons of GE HealthCare Technologies

  • Recent guidance cuts have lowered the FY26 EPS forecast to between $4.80 and $5.00, which is below market expectations, indicating potential challenges ahead.
  • Margin pressures due to inflation and rising costs for components like chips and oil have been cited as significant concerns, which could impact profitability.
  • Analyst downgrades from firms like JPMorgan and Citigroup, with price targets reduced from $80 to $65, reflect lowered expectations and could lead to further stock price declines.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$28.96 billion
P/E Ratio
15.23
Consensus Rating
Hold
Consensus Price Target
$80.63 (+26.5% Upside)
Volume
4.37 million shares
Average Volume
4.19 million shares
Today's Range
$61.00
$63.56
50-Day Range
$59.49
$75.63
52-Week Range
$58.75
$89.77
Dividend Yield
0.23%
Natera stock logo

48. Natera NASDAQ:NTRA

$201.13 +5.09 (+2.60%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Market Capitalization
$28.79 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$256.60 (+27.6% Upside)
Volume
778,470 shares
Average Volume
1.31 million shares
Today's Range
$197.16
$205.36
50-Day Range
$182.65
$219.82
52-Week Range
$131.81
$256.36
Dividend Yield
N/A
Centene stock logo

49. Centene NYSE:CNC

$58.01 -1.14 (-1.93%)
As of 01:28 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • Recent price target increases from analysts, including a significant boost to $68.00, suggest strong potential upside from the current stock price, which is around $54.44.
  • Centene Co. has received multiple "outperform" and "buy" ratings from various brokerages, indicating positive sentiment and confidence in the company's future performance.
  • The company operates in the healthcare sector, which is generally resilient and continues to grow, especially in government-sponsored programs like Medicaid and Medicare.

Cons of Centene

  • Some analysts have expressed concerns about execution, suggesting that the company needs to improve operational performance to realize its growth potential.
  • There is a lower consensus price target of around $42 from some brokerages, which could limit upside potential if this view gains traction among investors.
  • Despite recent price target increases, the overall sentiment remains mixed, with several analysts maintaining "hold" or "neutral" ratings, indicating caution.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$28.64 billion
P/E Ratio
N/A
Consensus Rating
Hold
Consensus Price Target
$55.88 (-3.7% Downside)
Volume
1.24 million shares
Average Volume
6.58 million shares
Today's Range
$57.93
$60.76
50-Day Range
$31.72
$59.34
52-Week Range
$25.08
$61.63
Dividend Yield
N/A
IQVIA stock logo

50. IQVIA NYSE:IQV

$168.97 -4.21 (-2.43%)
As of 01:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The current stock price is around $178, which may present a buying opportunity for investors looking for growth in the life sciences sector.
  • IQVIA Holdings Inc. has demonstrated strong financial performance, reporting a revenue increase of over 8% compared to the same quarter last year, indicating robust demand for its services.
  • The company has a solid return on equity of 30.50%, suggesting effective management and profitability, which can be attractive to investors seeking reliable returns.

Cons of IQVIA

  • The company has a relatively high debt-to-equity ratio of 2.20, which may raise concerns about financial leverage and the ability to manage debt obligations effectively.
  • Despite recent revenue growth, the stock has shown volatility, with a beta of 1.18, indicating that it may be more sensitive to market fluctuations, which could pose risks for conservative investors.
  • Some analysts have recently adjusted their price targets downward, reflecting a cautious outlook on the stock's near-term performance, which could deter potential investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$28.16 billion
P/E Ratio
20.90
Consensus Rating
Buy
Consensus Price Target
$225.69 (+33.6% Upside)
Volume
746,683 shares
Average Volume
1.91 million shares
Today's Range
$165.44
$171.97
50-Day Range
$156.42
$178.95
52-Week Range
$134.65
$247.04
Dividend Yield
N/A